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The cDNA coding for mature human a,-proteinase inhibitor (a,-PI) has been inserted into a variety of yeast 
expression vectors. Yeast cells transformed with these plasmids were then assayed for the production of 
mature. unglycosylated GI,-PI. The production level is optimal when the recombinant plasmid carries the 
TDH promoter, the complete 2~ and the leu2D selection marker. Biologically active recombinant CC,-PI can 
be purified either analytically, by affinity chromatography using a monoclonal antibody, or on a large scale, 
by a procedure involving precipitation of high-M, yeast material with polyethylene glycol 3300 followed 
by successive chromatography on DEAE-agarose, Zn-chelate agarose, K-chain agarose, heparin-agarose 
and aminohexyl-agarose. 
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1. INTRODUCTION 
Severe cui-PI hereditary deficiency is associated 
with reduced neutrophil elastase inhibition and 
hence with lung tissue degradation which results in 
the development of emphysema [1,2]. Replace- 
ment therapy with ai-PI to restore plasma anti- 
elastase activity requires large amounts of the pro- 
tein [3]. In this context, human W-PI has been 
cloned and expressed in E. coli [4,5] and yeast 
[6,7]. The recombinant W-PI has been purified to 
homogeneity and, although non-glycosylated, it 
exhibits similar physico-chemical and biological 
properties to the human plasma derivative [8-lo]. 
* To whom correspondence should be addressed 
Abbreviations: cur-PI, cyr-proteinase inhibitor, crr-anti- 
trypsin; r_Lyr-PI, recombinant cur-PI; PEG, polyethylene 
glycol; TDH3, glyceraldehyde-3-phosphate dehydro- 
genase; TNB, 4-nitrophenylsulfide 3,3’-dicarbonic acid 
In order to find therapeutic application, large 
quantities of active and highly pure (YI-PI will have 
to be provided regularly [ 111. In a continuing ef- 
fort to optimize the production of r-cui-PI in yeast, 
we report here the construction of a recombinant 
plasmid, pRIT12655, which directs the expression 
of the protein to high levels. In addition, we 
describe a protocol for the large-scale purification 
of r-cui-PI from yeast cells carrying the new 
plasmid. 
2. MATERIALS AND METHODS 
2.1. Products and procedures 
Restriction endonucleases and other DNA- 
modifying enzymes were used as recommended 
by the manufacturer (Boehringer-Mannheim). 
General cloning techniques were performed as 
described [ 121. 
Plasmids used in this report, pBR327, 
pRIT10787 and YIPS, have been described 
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[6,13,14]. The genotype of yeast strains lOS44C 
and TCYl is shown in table 1. 
Transformation of yeast strains, conditions for 
yeast cultivation, and preparation of extracts have 
been described [6,11]. 
Reagents and buffers were as in [lO,ll], 
Sepharose products were purchased from Phar- 
macia (Sweden), and x-chain agarose was syn- 
thesized as described [ 151. Monoclonal antibody 
against (or-PI, AATY6, has been described 
previously [ 161. 
2.2. Isolation of r-ffl-PI 
Small volumes (5 ml) of crude yeast extracts [6] 
containing 1 mM PMSF, 20 mM &mercapto- 
ethanol and 5 mM EDTA in 50 mM Tris-HCl buf- 
fer, pH 8.0, were centrifuged for 20 min at 16000 
x g to remove membrane fragments. This super- 
natant was supplemented with Triton WR1339, 
final concentration 0.1070, and applied to a column 
of immobilized monoclonal antibody raised 
against cur-PI (5 mg AATY6 coupled to 5 ml 
Sepharose 4B). The column was washed with 
10 mM sodium phosphate buffer, pH 7.5, contain- 
ing 150 mM NaCl and 0.1% Triton WR1339, and 
al-PI was eluted stepwise using the same buffer to 
which 1 M NaSCN had been added. 
Large volumes, up to 2.5 I, of crude yeast ex- 
tracts adjusted to pH 6.5 with solid Tris powder or 
10% acetic acid were incubated at 4°C with a final 
concentration of 6.5% PEG 3300 for 2 h and then 
centrifuged at 16000 x g for 1 h. The resulting 
clear extract was loaded onto a 2 1 column of 
DEAE-Sepharose FF equilibrated in 20 mM 
sodium phosphate buffer, pH 6.5. After washing, 
(YI-PI was eluted using 150 mM NaCl in the same 
buffer. The eluate was adjusted to pH 7.5 and 
loaded onto a 1 1 Zn-chelate column equilibrated 
in 25 mM sodium phosphate buffer, pH 7.5, con- 
taining 200 mM NaCl. The (or-PI fraction was 
recovered after elution with 50 mM phosphate 
buffer, pH 5.5, 200 mM NaCl, 10% ethylene 
glycol. EDTA was added to 20 mM, and the pH 
was raised to 8.5 by addition of solid Tris powder. 
This pool was then applied to a 0.5 1 x-chain 
agarose column, and al-PI was eluted with an ex- 
cess of TNB- in the starting buffer [ 11, IS]. Pooled 
fractions were dialysed against 20 mM phosphate 
buffer, pH 7.5, and loaded onto a heparin-agarose 
column, serially connected to a final AH- 
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Sepharose column equilibrated in 20 mM 
phosphate buffer, pH 7.5. The AH-Sepharose was 
then washed with 50 mM imidazole buffer, pH 
5.5, and al-PI was eluted by a linear NaCl gradient 
(25-300 mM) in this buffer. 
3. RESULTS AND DISCUSSION 
3.1. Construction and description of recombinant 
plasmids for expression of human CY,-PI in 
yeasts 
Expression cassettes for synthesis of mature 
human cur-PI contain the mature structural gene se- 
quence fused via a BarnHI site overlapping the 
second codon to BamHI sites created by in vitro 
manipulation at the ATG initiation codons of 
ARG3 or TDH3 promoter fragments [6]. The 
(YI-PI coding sequence is fused 3’ to a 1150 bp 
fragment carrying the transcription termination 
signal for the yeast ARG3 gene. Cassettes can be 
excised as 3870 bp (ARG3 promoter) or 3450 bp 
(TDH3 promoter) Hind111 fragments for insertion 
into yeast shuttle vectors. Three types of vectors 
were used in this study (table 1). Plasmid 
pRIT12348 was obtained from pRIT10787 [6] by 
replacement of the ARG3 with a TDH3 promoter 
fragment. The vector pRIT12645 comprises the 
complete sequence of yeast & DNA inserted at the 
EcoRI site of pBR327, a 2200 bp yeast LEU2 gene 
fragment as selector inserted at the Safl site of 
pBR327, and the ARG3_cyr-PI expression cassette 
inserted by blunt end cloning at the BarnHI site of 
the plasmid. The parent vector is described 
elsewhere [171. Expression vectors pRIT12653 and 
pRIT12655 carry the ARG3<r-PI and 
TDH3-al-PI expression cassettes, respectively, in- 
serted by blunt end cloning at the BarnHI site of 
recipient vector pRIT12495. This vector plasmid 
consists of YIp5 (URA3 yeast gene inserted on 
pBR322) together with the full + DNA sequence 
and the leu2D gene from JDB219 [18]. The feature 
of this vector is the double selection available in 
appropriate yeast strains enabling variation in 
copy number from moderate (URA3 selection) to 
high (leu2D selection) depending on the selective 
medium. The structure of the most efficient vector 
(pRIT12655) for the expression of human cry-PI 
cDNA is shown in fig.1. The plasmids were in- 
troduced into recipient strains lOS44C or TCYl 
(table 1) and assayed for expression. 
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Table 1 
cul-PI expression vectors and strains 
August 1986 
Transformed 
yeast strain 
Recipient 
strain 
Vector W-PI expression 
cassette 
2~ sequences Selection 
Promoter Terminator 
Y157 
Y398 
Y521 
Y497 
lOS44C pRIT 12348 TDH3 ARG3 partial LEU2 
TCYl pRIT 12645 ARG3 ARG3 complete LEU2 
TCYl pRIT 12653 ARG3 ARG3 complete leu2D,URA3 
TCYl pRIT 12655 TDH3 ARG3 complete leu2D,URA3 
Strain lOS44C has the leu2-3, leu2-112, pep4-3 genotype. Strain TCY 1 is a cir’ derivative of lOS44C 
3.2. Expression levels of cul-PI in yeast 
Yeast strains, Y398 and Y157 (table l), were 
grown to an A650 of 0.5 and total protein COmpOSi- 
tion was analyzed on SDS-polyacrylamide gels. As 
seen in fig.2A, a minor band with respect to the 
total protein assortment appears at M 43000 cor- 
responding to W-PI, as confirmed by immunoblot- 
ting (not shown), this band being more prominent 
in strain Y157 than in Y398. On the other hand, a 
similar analysis on proteins derived from strains 
Y521 and Y497 shows that W-PI is one of the ma- 
EcoRl 
EcoRl 
EcoRl 
Barn H I EcoRl 
Fig. 1. Schematic representation of yeast plasmid 
pRIT12655 (see section 3). 
jor protein constituents, the optimal expression 
level again being obtained when the vector carries 
the pTDH3_cyi-PI-tARG3 expression cassette 
(table 1, fig.2B). In leucine-deprived medium, 
transformed strains carrying the leu2D selection 
marker grow more slowly (generation time, 6 h) 
than those having the normal LEU2 selector 
abed ab cd 
. . 1 
66K 
43K 
25.4K 
14.3 K 
6.5 K 
4 
92.5 K 
66K 
43K 
31 K 
21.5 K 
l4K 
A B 
Fig.2. SDS-polyacrylamide g l electrophoresis of total 
yeast proteins. Ac,d, strain Y398 (pARG3) and strain 
Y157 (pTDH3); Ba,b, strain Y521 (pARG3) and strain 
Y497 (pTDH3); Ab,Bc, control strains carrying recipient 
vectors pRIT12377 [17] and pRIT12495, respectively; 
Aa,Bd, molecular mass markers. 
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Fig.3. (a) Weight of yeast cells recovered during large- 
scale fermentation of yeast strain Y497. (b) Protein 
composition of the final extract as revealed by SDS- 
polyacrylamide gel electrophoresis. Lane 1, 2 and 3, 150, 
100 and 5Opg proteins respectively; lane 4, molecular 
mass markers. 
.c d,e 
(generation time, 3 h), a result observed for small- 
and large-scale fermentations (fig.3a). Despite its 
slow growth, strain Y497 produces unaltered @,-PI 
as the major protein (5-6% of soluble proteins) 
even during fermentation for 2 days up to 35 g wet 
yeast per 1 medium (fig.3b). 
3.3. Purification of r-cyr-PI derived from yeast 
strain Y497 
It is relatively easy to isolate r-al-PI with a puri- 
ty of at least 80% using a monoclonal antibody im- 
mobilized on Sepharose 4B. In this respect the an- 
tibody AATY6 is particularly suited for the 
analytical purification of al-PI, due to its 
moderatq affinity for the antigen (& = 5 x 
10v9 M). Recovery of active al-PI from the affini- 
ty column can therefore be achieved under rather 
mild conditions (1 M NaSCN). However, ex- 
tending this procedure to large-scale purification 
of al-PI would require prohibitive amounts of 
monoclonal antibodies. We therefore chose to 
develop an alternative isolation scheme, suited for 
treatment of kilogram quantities of yeast involving 
(i) DEAE chromatography (fig.4b,c) which yields 
a clear protein fraction slightly enriched in al-PI 
fg’h 
Fig.4. Large-scale isolation of CU,-PI from yeast strain Y497. DEAE-chromatography: flow-through (b) and stepwise 
elution (c); Zn-chelate chromatography: flow-through (d) and stepwise elution (e); x-chain chromatography: flow- 
through (g) and stepwise elution (h); complete NaCl gradient elution from AH-Sepharose (i); molecular mass markers 
(a,f). 
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(10-l 1 Yo) but essentially free from all added 
reagents; (ii) a Zn-chelate column from which 
cul-PI elutes about 25% pure (fig.4d,e); (iii) x- 
chain-agarose chromatography which increases 
(YI-PI purity up to 70% (fig.4g,h); and (iv) linked 
heparin- and AH-Sepharose columns which yield a 
highly purified inhibitor (fig.4i). Omission of the 
preliminary clarification step (PEG precipitation) 
drastically reduced the resolution and yield in the 
subsequent DEAE chromatography. 
The combination of four successive affinity 
chromatographies, following the clarification step, 
is required to obtain a highly purified product 
(>95%). 
Recombinant al-PI, purified as described, was 
recovered with an overall yield of 40% and 
displayed an inhibitory activity (not shown) 
equivalent o that of its plasma counterpart in the 
inactivation of bovine trypsin and porcine elastase, 
measurements which have been shown previously 
Vll. 
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